Inter Partes Review in the Life Sciences Industry

May 2019

Partner David Berl and associates Michael Xun Liu and Jingyuan Luo recently co-authored an article for IAM Life Sciences: Key Issues for Senior Life Sciences Executives 2019 entitled “Inter Partes Review in the Life Sciences Industry.” The article covers recent trends in life sciences IPR proceedings and examines the interaction between IPR, Hatch-Waxman, and biosimilar litigation.

Click here to read the article. To view the IAM Life Sciences guide in full, please go to

back to top